Talampanel (BioDeep_00000009499)
代谢物信息卡片
化学式: C19H19N3O3 (337.1426)
中文名称: (8R)-7-乙酰基-5-(4-氨基苯基)-8,9-二氢-8-甲基-7H-1,3-二氧杂环戊烯并[4,5-H][2,3]苯并二氮杂卓
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2CC1C)OCO3
InChI: InChI=1S/C19H19N3O3/c1-11-7-14-8-17-18(25-10-24-17)9-16(14)19(21-22(11)12(2)23)13-3-5-15(20)6-4-13/h3-6,8-9,11H,7,10,20H2,1-2H3/t11-/m1/s1
描述信息
C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant
Same as: D02696
Talampanel (LY300164) is an orally and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor antagonis with anti-seizure activity[1]. Talampanel (IVAX) has neuroprotective effects in rodent stroke models[2]. Talampanel attenuates caspase-3 dependent apoptosis in mouse brain[2].
同义名列表
5 个代谢物同义名
数据库引用编号
13 个数据库交叉引用编号
- ChEBI: CHEBI:34992
- KEGG: C13670
- KEGGdrug: D02696
- PubChem: 164509
- Metlin: METLIN69623
- DrugBank: DB04982
- ChEMBL: CHEMBL61872
- CAS: 161832-65-1
- PMhub: MS000023291
- PubChem: 586262
- NIKKAJI: J722.092H
- medchemexpress: HY-15079
- KNApSAcK: 34992
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Robert M Pascuzzi, Jeremy Shefner, Amy S Chappell, John S Bjerke, Roy Tamura, Vinay Chaudhry, Lora Clawson, Lisa Haas, Jeffrey D Rothstein. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
2010 May; 11(3):266-71. doi:
10.3109/17482960903307805. [PMID: 19961264] - P Buchwald, A Juhász, C Bell, M Pátfalusi, P Kovács, G Hochhaus, J Howes, N Bodor. Influence of the N-acetylation polymorphism on the metabolism of talampanel: an investigation in fasted and fed subjects genotyped for NAT2 variants.
Die Pharmazie.
2006 Feb; 61(2):125-34. doi:
. [PMID: 16526560] - Peter Buchwald, Attila Juhász, Cynthia Bell, Márta Pátfalusi, John Howes, Nicholas Bodor. Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.
Journal of pharmacokinetics and pharmacodynamics.
2005 Aug; 32(3-4):377-400. doi:
10.1007/s10928-005-0001-y. [PMID: 16320099] - K K Borowicz, M Swiader, M Wielosz, S J Czuczwar. Influence of the combined treatment of LY 300164 (an AMPA/kainate receptor antagonist) with adenosine receptor agonists on the electroconvulsive threshold in mice.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
2004 Oct; 14(5):407-12. doi:
10.1016/j.euroneuro.2003.12.003. [PMID: 15336302] - Yvonne M Langan, Richard Lucas, Haley Jewell, N Toublanc, H Schaefer, Josemir W A S Sander, Philip N Patsalos. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy.
Epilepsia.
2003 Jan; 44(1):46-53. doi:
10.1046/j.1528-1157.2003.128902.x. [PMID: 12581229] - K K Borowicz, M Swiader, W Zgrajka, C Sawulski, W A Turski, S J Czuczwar. Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
2002 Dec; 53(4 Pt 2):859-69. doi:
. [PMID: 12510869] - Mariusz Swiader, Kinga K Borowicz, Jacek Porebiak, Zdzisław Kleinrok, Stanisław J Czuczwar. Influence of agents affecting voltage-dependent calcium channels and dantrolene on the anticonvulsant action of the AMPA/kainate receptor antagonist LY 300164 in mice.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
2002 Aug; 12(4):311-9. doi:
10.1016/s0924-977x(02)00045-7. [PMID: 12126870] - K K Borowicz, Z Kleinrok, S J Czuczwar. The AMPA/kainate receptor antagonist, LY 300164, increases the anticonvulsant effects of diazepam.
Naunyn-Schmiedeberg's archives of pharmacology.
2000 Jun; 361(6):629-35. doi:
10.1007/s002100000237. [PMID: 10882038] - S J Czuczwar, M Swiader, H Kuźniar, M Gasior, Z Kleinrok. LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs.
European journal of pharmacology.
1998 Oct; 359(2-3):103-9. doi:
10.1016/s0014-2999(98)00632-3. [PMID: 9832379] - D Bleakman, B A Ballyk, D D Schoepp, A J Palmer, C P Bath, E F Sharpe, M L Woolley, H R Bufton, R K Kamboj, I Tarnawa, D Lodge. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles.
Neuropharmacology.
1996; 35(12):1689-702. doi:
10.1016/s0028-3908(96)00156-6. [PMID: 9076748] - J A Eckstein, S P Swanson. Determination of a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor antagonist (LY300164) and its N-acetyl metabolite in mouse, rat, dog, and monkey plasma using high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical applications.
1995 Jun; 668(1):153-8. doi:
10.1016/0378-4347(95)00058-q. [PMID: 7550972]
